Structured intelligence coverage

Structured records are temporarily unavailable. The published profile and its source ledger remain accessible.

Identity checks do not refresh the age of governance evidence. Open a record for its source date and review state.

Profile

Identity, professional record and current appointments.

Overview

Professional record at a glance

A concise summary of information supported by the cited public sources. Missing information is treated as unknown, not as a negative finding.

Current roles
Not availableAdditional role information may appear below
Board positions
Not establishedNo board position is currently listed on this profile
Committee roles
1Roles supported by the sources cited on this profile
Qualifications
Not establishedNo qualification is currently confirmed by the cited sources

Professional narrative

About

Former President and Chief Executive Officer of Memorial Sloan Kettering Cancer Center from 2010 to 2022, where he continues to oversee the Craig Thompson Lab. Co-founder of Agios Pharmaceuticals, Inc. Former director of Merck & Co., Inc. Member of National Academy of Sciences and National Academy of Medicine.

Sources are shown with the information they support.

Current roles

Appointments & responsibilities

A current role is not yet confirmed. Additional information may be available in the Sources section.

Governance

Board appointments, committee responsibilities and disclosed relationships.

Committee appointments across companies · Temporarily unavailable

Structured records for this section are unavailable. This does not establish that no records exist. Published profile sources remain in Evidence & History.

Connections

Explore the roles, education and affiliations published in this record.

No public connections are published in this record yet.

Relationship map

Connected through the public record

Direct relationships from verified facts and published résumé records. Private connections are excluded.

People connections are private by default.

No person-to-person relationship is exposed by this public record. Shared boards, employment, and Council activity require a permissioned view.

Claim to review relationship visibility

Direct public links only

Only published affiliations are shown here. Private relationships require authorized access.

Experience

Career history, education, credentials and public contributions.

Published record

Featured coverage

Selected publications and public sources used to establish this profile. Inclusion records provenance; it is not an endorsement.

Source 1 · Sec FilingMPLT DEF 14A executive officersSupports Executive company, Executive title.Open sourceSource 2 · Sec FilingHTFL DEF 14A executive officersSupports Executive company, Executive title.Open sourceSource 3 · Sec FilingAPGE DEF 14A executive officersSupports AI and ML experience, Cybersecurity experience, Executive company, Executive title, Technology background.Open sourceSource 4 · Sec FilingRegeneron Pharmaceuticals, Inc. director board sourceSupports Board membership, Committee assignments, Director since, Board independence.Open sourceSource 5 · Sec FilingLRMR DEF 14A executive officersSupports Executive company, Executive title.Open sourceSource 6 · Sec FilingNUVL 10-K executive officersSupports Executive company, Executive title.Open sourceSource 7 · Sec FilingVRTX 10-K executive officersSupports Executive company, Executive title.Open sourceSource 8 · Sec FilingREGN DEF 14A director slateSupports AI and ML experience, Board role, Committee assignments, Cybersecurity experience, Technology background.Open source

Basis

Identifiers, sources, dates and record limitations.

Identifiers

Alpha ID
alpha:person:craig-b-thompson-m-d
Record version
public-0

Published evidence records

10 evidence records, matching Agent View. Records may refer to different locations or observations in the same document. This count is not a count of independent corroborating sources.

  1. MPLT DEF 14A executive officers

    sec filing · Source published: Apr 29, 2026 · Retrieved: May 4, 2026

    Supports 2 claims
    • Executive company: Executive at MapLight Therapeutics, Inc. · Claim reviewed: May 4, 2026
    • Executive title: Executive title: President, Chief Executive Officer and Director · Claim reviewed: May 4, 2026

  2. HTFL DEF 14A executive officers

    sec filing · Source published: Apr 29, 2026 · Retrieved: May 4, 2026

    Supports 2 claims
    • Executive company: Executive at Heartflow, Inc. · Claim reviewed: May 4, 2026
    • Executive title: Executive title: Chief Medical Officer · Claim reviewed: May 14, 2026

  3. APGE DEF 14A executive officers

    sec filing · Source published: Apr 24, 2026 · Retrieved: May 14, 2026

    Supports 5 claims
    • AI and ML experience: AI and ML experience: not identified in the cited filing · Claim reviewed: May 15, 2026
    • Cybersecurity experience: Cybersecurity experience: not identified in the cited filing · Claim reviewed: May 15, 2026
    • Executive company: Executive at Apogee Therapeutics · Claim reviewed: May 14, 2026
    • Executive title: Executive title: Chief Medical Officer · Claim reviewed: May 14, 2026
    • Technology background: Technology background: not identified in the cited filing · Claim reviewed: May 15, 2026

  4. Regeneron Pharmaceuticals, Inc. director board source

    sec filing · Source published: Apr 24, 2026 · Retrieved: May 3, 2026

    Supports 3 claims
    • Board independence: Independent director · Claim reviewed: May 3, 2026
    • Board membership: Serves on the board of Regeneron Pharmaceuticals, Inc. · Claim reviewed: May 3, 2026
    • Committee assignments: No committee assignment disclosed in the cited filing · Claim reviewed: May 3, 2026

  5. LRMR DEF 14A executive officers

    sec filing · Source published: Apr 20, 2026 · Retrieved: May 4, 2026

    Supports 2 claims
    • Executive company: Executive at Larimar Therapeutics, Inc. · Claim reviewed: May 4, 2026
    • Executive title: Executive title: President and Chief Executive Officer · Claim reviewed: May 4, 2026

  6. NUVL 10-K executive officers

    sec filing · Source published: Feb 26, 2026 · Retrieved: May 1, 2026

    Supports 2 claims
    • Executive company: Executive at Nuvalent Inc · Claim reviewed: May 3, 2026
    • Executive title: Executive title: Chief Medical Officer · Claim reviewed: May 14, 2026

  7. VRTX 10-K executive officers

    sec filing · Source published: Feb 13, 2026 · Retrieved: Apr 25, 2026

    Supports 2 claims
    • Executive company: Executive at Vertex Pharmaceuticals Incorporated · Claim reviewed: May 3, 2026
    • Executive title: Executive title: Executive Vice President, Global Medicines Development and Medical Affairs, and Chief Medical Officer · Claim reviewed: May 3, 2026

  8. REGN DEF 14A director slate

    sec filing · Source published: Apr 29, 2025 · Retrieved: May 15, 2026

    Supports 5 claims
    • AI and ML experience: AI and ML experience: not identified in the cited filing · Claim reviewed: May 15, 2026
    • Board role: Board role: Director · Claim reviewed: May 15, 2026
    • Committee assignments: Committee assignments: Technology · Claim reviewed: May 15, 2026
    • Cybersecurity experience: Cybersecurity experience: not identified in the cited filing · Claim reviewed: May 15, 2026
    • Technology background: Technology background: not identified in the cited filing · Claim reviewed: May 15, 2026

  9. NUVL executive roster source

    sec filing · Source published: Date unavailable · Retrieved: May 3, 2026

    Supports 5 claims
    • AI expertise: AI expertise: not identified in the cited filing · Claim reviewed: May 3, 2026
    • AI governance relevance: AI governance relevance: not identified in the cited filing · Claim reviewed: May 3, 2026
    • Executive company: Executive at Nuvalent Inc · Claim reviewed: May 3, 2026
    • Executive function: Other Executive (OTHER_EXECUTIVE) · Claim reviewed: May 3, 2026
    • Executive title: Executive title: Chief Medical Officer · Claim reviewed: May 14, 2026

  10. VRTX executive roster source

    sec filing · Source published: Date unavailable · Retrieved: May 3, 2026

    Supports 5 claims
    • AI expertise: AI expertise: not identified in the cited filing · Claim reviewed: May 3, 2026
    • AI governance relevance: AI governance relevance: not identified in the cited filing · Claim reviewed: May 3, 2026
    • Executive company: Executive at Vertex Pharmaceuticals Incorporated · Claim reviewed: May 3, 2026
    • Executive function: Other Executive (EVP) · Claim reviewed: May 3, 2026
    • Executive title: Executive title: Executive Vice President, Global Medicines Development and Medical Affairs, and Chief Medical Officer · Claim reviewed: May 3, 2026

Sources

Sources and published information

Each item links to the public source used to support it. When sources disagree, the item is clearly marked for review.

AI and ML experience · CorroboratedAI and ML experience: not identified in the cited filingSupported by 2 public records2 sources
Verification
Corroborated
Confidence
72%
Last reviewed
May 15, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 15, 2026

  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 14, 2026

AI expertise · CorroboratedAI expertise: not identified in the cited filingSupported by 2 public records2 sources
Verification
Corroborated
Confidence
94%
Last reviewed
May 3, 2026

  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 3, 2026

  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 3, 2026

AI governance relevance · CorroboratedAI governance relevance: not identified in the cited filingSupported by 2 public records2 sources
Verification
Corroborated
Confidence
94%
Last reviewed
May 3, 2026

  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 3, 2026

  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 3, 2026

Board independence · Source reportedIndependent director1 source
Verification
Source reported
Confidence
95%
Last reviewed
May 3, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 3, 2026

Board membership · Source reportedServes on the board of Regeneron Pharmaceuticals, Inc.Supported by 2 public records1 source
Verification
Source reported
Confidence
95%
Last reviewed
May 3, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 3, 2026

Board role · Source reportedBoard role: Director1 source
Verification
Source reported
Confidence
92%
Last reviewed
May 15, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 15, 2026

Committee assignments · Source reportedNo committee assignment disclosed in the cited filing1 source
Verification
Source reported
Confidence
95%
Last reviewed
May 3, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 3, 2026

Committee assignments · Source reportedCommittee assignments: Technology1 source
Verification
Source reported
Confidence
88%
Last reviewed
May 15, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 15, 2026

Cybersecurity experience · CorroboratedCybersecurity experience: not identified in the cited filingSupported by 2 public records2 sources
Verification
Corroborated
Confidence
72%
Last reviewed
May 15, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 14, 2026

  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 15, 2026

Executive company · Source reportedExecutive at Apogee Therapeutics1 source
Verification
Source reported
Confidence
94%
Last reviewed
May 14, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 14, 2026

Executive company · Source reportedExecutive at Heartflow, Inc.1 source
Verification
Source reported
Confidence
94%
Last reviewed
May 4, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 4, 2026

Executive company · Source reportedExecutive at Larimar Therapeutics, Inc.1 source
Verification
Source reported
Confidence
94%
Last reviewed
May 4, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 4, 2026

Executive company · Source reportedExecutive at MapLight Therapeutics, Inc.1 source
Verification
Source reported
Confidence
94%
Last reviewed
May 4, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 4, 2026

Executive company · CorroboratedExecutive at Nuvalent IncSupported by 2 public records2 sources
Verification
Corroborated
Confidence
94%
Last reviewed
May 3, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 1, 2026

  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 3, 2026

Executive company · CorroboratedExecutive at Vertex Pharmaceuticals IncorporatedSupported by 2 public records2 sources
Verification
Corroborated
Confidence
94%
Last reviewed
May 3, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed Apr 25, 2026

  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 3, 2026

Executive function · Source reportedOther Executive (EVP)1 source
Verification
Source reported
Confidence
94%
Last reviewed
May 3, 2026

  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 3, 2026

Executive function · Source reportedOther Executive (OTHER_EXECUTIVE)1 source
Verification
Source reported
Confidence
94%
Last reviewed
May 3, 2026

  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 3, 2026

Executive title · CorroboratedExecutive title: Chief Medical OfficerSupported by 4 public records4 sources
Verification
Corroborated
Confidence
94%
Last reviewed
May 14, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 4, 2026

  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 14, 2026

  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 1, 2026

  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 3, 2026

Executive title · CorroboratedExecutive title: Executive Vice President, Global Medicines Development and Medical Affairs, and Chief Medical OfficerSupported by 2 public records2 sources
Verification
Corroborated
Confidence
94%
Last reviewed
May 3, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed Apr 25, 2026

  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 3, 2026

Executive title · Source reportedExecutive title: President and Chief Executive Officer1 source
Verification
Source reported
Confidence
94%
Last reviewed
May 4, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 4, 2026

Executive title · Source reportedExecutive title: President, Chief Executive Officer and Director1 source
Verification
Source reported
Confidence
94%
Last reviewed
May 4, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 4, 2026

Technology background · CorroboratedTechnology background: not identified in the cited filingSupported by 2 public records2 sources
Verification
Corroborated
Confidence
72%
Last reviewed
May 15, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 14, 2026

  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 15, 2026

View all sources10 records
  1. SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 4, 2026

    Supports: Executive company · Executive title

  2. SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 4, 2026

    Supports: Executive company · Executive title

  3. SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 14, 2026

    Supports: AI and ML experience · Cybersecurity experience · Executive company · Executive title · Technology background

  4. SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 3, 2026

    Supports: Board membership · Committee assignments · Director since · Board independence

  5. SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 4, 2026

    Supports: Executive company · Executive title

  6. SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 1, 2026

    Supports: Executive company · Executive title

  7. SEC EDGAR

    Sec Filing · Tier 3 · Reviewed Apr 25, 2026

    Supports: Executive company · Executive title

  8. SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 15, 2026

    Supports: AI and ML experience · Board role · Committee assignments · Cybersecurity experience · Technology background

  9. SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 3, 2026

    Supports: AI expertise · AI governance relevance · Executive company · Executive function · Executive title

  10. SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 3, 2026

    Supports: AI expertise · AI governance relevance · Executive company · Executive function · Executive title